Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.

Autor: Hanrahan JP; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., de Boer IH; Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington., Bakris GL; Department of Medicine, Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, Illinois., Wilson PJ; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Wakefield JD; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Seferovic JP; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Chickering JG; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Chien YT; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Carlson K; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Cressman MD; Cardiovascular/Metabolic Unit, Covance Inc., Princeton, New Jersey., Currie MG; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Milne GT; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts., Profy AT; Cyclerion Therapeutics, Inc., Cambridge, Massachusetts.

Publikováno v: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2020 Dec 31; Vol. 16 (1), pp. 59-69. Date of Electronic Publication: 2020 Dec 16.